Literature DB >> 10955770

Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers.

N J Donato, M Talpaz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10955770

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Feature-similarity protein classifier as a ligand engineering tool.

Authors:  Sridhar Maddipati; Ariel Fernández
Journal:  Biomol Eng       Date:  2006-10-10

Review 2.  Kinase packing defects as drug targets.

Authors:  Alejandro Crespo; Ariel Fernández
Journal:  Drug Discov Today       Date:  2007-10-30       Impact factor: 7.851

Review 3.  Mechanisms of transformation by the BCR/ABL oncogene.

Authors:  M Sattler; J D Griffin
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

4.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

5.  An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

Authors:  Ariel Fernández; Angela Sanguino; Zhenghong Peng; Eylem Ozturk; Jianping Chen; Alejandro Crespo; Sarah Wulf; Aleksander Shavrin; Chaoping Qin; Jianpeng Ma; Jonathan Trent; Yvonne Lin; Hee-Dong Han; Lingegowda S Mangala; James A Bankson; Juri Gelovani; Allen Samarel; William Bornmann; Anil K Sood; Gabriel Lopez-Berestein
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.